Efficacy of growth hormone therapy in adults with childhood-onset growth hormone deficiency
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: Growth hormone (GH) plays a key role in the regulation of bodycomposition, lipid metabolism, and quality of life in adults with GH deficiency (GHD). This study investigated changes in laboratory findings and body compositionafter GH recommencement for adult GHD and analyzed correlation between GHinterruption period and endocrine or anthropometric parameters. Methods: A total of 45 patients (17 females and 28 males) diagnosed withchildhood-onset GHD (CO-GHD) were investigated and all patients had organicbrain lesions. Patients diagnosed CO-GHD were retested to confirm adult GHD atage 20.4±5.0 years (18.0–32.1 years). Recombinant human GH was administered ata dose of 0.44 mg/day. Clinical and laboratory parameters such as weight, height,body mass index (BMI), serum insulin-like growth factor 1 (IGF-1), serum totalcholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein(LDL) cholesterol, and triglyceride levels, were compared between baseline and12 months after treatment using paired t-test. In addition, correlation between GHinterruption period and clinical parameters including BMI, lipid profile, IGF-1, andIGFBP-3, was analyzed. Results: Of 45 patients, 33 patients had GH interruption period of 4.3±3.6 years(0.7–12.5 years). Serum HDL-cholesterol level increased significantly, whereas LDLcholesteroldecreased after 1 year of GH replacement therapy. However, bodyweight and BMI showed no significant changes after 1 year of GH replacementtherapy. There were no significant correlations between GH interruption period andlipid profile or anthropometric parameters. Conclusion: BMI and body weight were not affected by GH replacement. However,GH replacement in adults with GHD offers benefits in lipid metabolism.
Abstract
Purpose: Growth hormone (GH) plays a key role in the regulation of bodycomposition, lipid metabolism, and quality of life in adults with GH deficiency (GHD). This study investigated changes in laboratory findings and body compositionafter GH recommencement for adult GHD and analyzed correlation between GHinterruption period and endocrine or anthropometric parameters. Methods: A total of 45 patients (17 females and 28 males) diagnosed withchildhood-onset GHD (CO-GHD) were investigated and all patients had organicbrain lesions. Patients diagnosed CO-GHD were retested to confirm adult GHD atage 20.4±5.0 years (18.0–32.1 years). Recombinant human GH was administered ata dose of 0.44 mg/day. Clinical and laboratory parameters such as weight, height,body mass index (BMI), serum insulin-like growth factor 1 (IGF-1), serum totalcholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein(LDL) cholesterol, and triglyceride levels, were compared between baseline and12 months after treatment using paired t-test. In addition, correlation between GHinterruption period and clinical parameters including BMI, lipid profile, IGF-1, andIGFBP-3, was analyzed. Results: Of 45 patients, 33 patients had GH interruption period of 4.3±3.6 years(0.7–12.5 years). Serum HDL-cholesterol level increased significantly, whereas LDLcholesteroldecreased after 1 year of GH replacement therapy. However, bodyweight and BMI showed no significant changes after 1 year of GH replacementtherapy. There were no significant correlations between GH interruption period andlipid profile or anthropometric parameters. Conclusion: BMI and body weight were not affected by GH replacement. However,GH replacement in adults with GHD offers benefits in lipid metabolism.
참고문헌 (11)
- Inzaghi E, "The Challenge of Growth Hormone Deficiency Diagnosis and Treatment during the Transition from Puberty into Adulthood", Front Endocrinol, 4, pp.34~ (2013)
- Reed ML, "Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement", Front Endocrinol, 4, pp.64~ (2013)
- Cook DM, "A review of guidelines for use of growth hormone in pediatric and transition patients", Pituitary, 15, pp.301~310 (2012)
- Cook DM, "American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients -2009 update", Endocr Pract, 15(Suppl 2), pp.1~29 (2009)
- Molitch ME, "Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline", J Clin Endocrinol Metab, 96, pp.1587~1609 (2011)
- Duntas LH, "Thyroid disease and lipids", Thyroid, 12, pp.287~293 (2002)
- Maison P, "Impact of growth hormone (GH)treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials", J Clin Endocrinol Metab, 89, pp.2192~2199 (2004)
- Ho KK, "Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia", Eur J Endocrinol, 157, pp.695~700 (2007)
- Barake M, "Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis", J Clin Endocrinol Metab (2014)
- Kuzma M, "Impact of the growth hormone replacement on bone status in growth hormone deficient adults", Growth Horm IGF Res, 24, pp.22~28 (2014)
- Kołtowska-Häggstrom M, "Discontinuation of growth hormone (GH) treatment during the transition phase is an important factor determining the phenotype of young adults with nonidiopathic childhood-onset GH deficiency", J Clin Endocrinol Metab, 95, pp.2646~2654 (2010)